Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GTx falls on poor Phase III prostate cancer data

This article was originally published in Scrip

Executive Summary

GTX's toremifene failed to significantly reduce the incidence of prostate cancer in men with premalignant prostate lesions, show top-line results from a GTx-sponsored trial. The company's share price fell by 50% to $2.00 on Nasdaq when the news was announced earlier this week.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008961

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel